Alonso M, Támbara Y, López M, Aguilar JC, Mayo O, Prieto E, Cremata J, Gerwig G, Kamerling H, Hardy E

Language: English
References: 28
Page: 87-101
PDF size: 284.83 Kb.

ABSTRACT

Acemannan from Aloe barbadensis was obtained with four processes: 1) size exclusion chromatography (SEC) using Sepharose CL-4B matrix followed by ethanolic precipitation; 2) SEC, ultrafiltration using hollow-fiber cartridges (30 kDa or 0.1 µm) and ethanolic precipitation; 3) SEC, precipitation with cetyltrimethylammonium bromide (CTAB) and ethanolic precipitation; and 4) direct precipitation with CTAB and ethanolic precipitation. The detergent CTAB was effective to concentrate chromatographic eluates (process 3) and allowed the direct isolation and purification of acemannan from crude ethanolic extracts (process 4), without recurring to SEC. Process 4 also decreases operation time (9 days vs. 15 days in process 3), and costs regarding raw materials. Both processes generate materials devoid of detectable levels of anthraquinones and contaminating DNA, and proteins below 5% of dry weight. This material was essentially made of mannose; 97% obtained in processes 1-3 and 75% in process 4, with a molecular mass ranging from 2000 to 5000 Mr according to G5000 PW SEC. Acemannan in dry form was sterilized at the optimal 10 kGy γ-radiation dose, and retained both its physical-chemical properties and adjuvanticity for HBsAg co-delivered by the nasal route in mice. The mixture of acemannan-1% benzyl alcohol (w/v) does not affect the adjuvanticity. The total carbohydrates content, SEC-HPLC, pH, microbial limit and organoleptic characteristics of the irradiated polysaccharide suspended in phosphate buffer remained stable at -20 ºC for at least 6 months of storage. These results may be useful for designing processes for producing pharmaceutical quality acemannan to be used in vaccine clinical studies.

REFERENCES

1. Manna S, McAnalley BH. Determination of the position of the O-acetyl group in a beta-(1-->4)-mannan (acemannan) from Aloe barbardensis Miller. Carbohydr Res. 1993;241:317-9.

2. Kaufman T, Newman AR, Wexler MR. Aloe vera and burn wound healing. Plast Reconstr Surg. 1989;83(6):1075-6.

3. Lee JK, Lee MK, Yun YP, Kim Y, Kim JS, Kim YS, et al. Acemannan purified from Aloe vera induces phenotypic and functional maturation of immature dendritic cells. Int Immunopharmacol. 2001;1(7):1275-84.

4. Yates KM, Rosenberg LJ, Harris CK, Bronstad DC, King GK, Biehle GA, et al. Pilot study of the effect of acemannan in cats infected with feline immunodeficiency virus. Vet Immunol Immunopathol. 1992;35(1-2):177-89.

5. Zhang L, Tizard IR. Activation of a mouse macrophage cell line by acemannan: the major carbohydrate fraction from Aloe vera gel. Immunopharmacology. 1996;35(2):119-28.

6. Kemper KJ, Chiou V. Aloe vera: The Longwood Herbal Task Force and The Center for Holistic Pediatric Education and Research; 1999.

7. Kahlon JB, Kemp MC, Yawei N, Carpenter RH, Shannon WM, McAnalley BH. In vitro evaluation of the synergistic antiviral effects of acemannan in combination with azidothymidine and acyclovir. Mol Biother. 1991;3(4):214-23.

8. McAnalley BH, inventor; Carrington Lab Inc., assignee. Use of acemannan. EP 0619117A2. 1989 Aug 3.

9. Nordgrem RM, inventor; Solvay Animal Health, Inc., assignee. Vaccine containing acemannan as an adjuvant. International patent WO/1993/014195. 1993 Jul 22.

10. Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol. 2004;82(5):488-96.

11. Aguilar JC, Muzio VL, Leal MJ, Guillén GE, Pentón E, Véliz G, et al., inventors; Centro de Ingeniería Genética y Biotecnología, assignee. Immunopotentiating formulations for vaccinal use. International Patent WO 09839032. 1998 Mar 5.

12. Daniels L, Hanson RS, Phillips JA. Chemical analysis. In: Gerhardt P, Murray RGE, Wood WA, Krieg NR, editors. Methods for General and Molecular Bacteriology. Washington DC: American Society for Microbiology; 1994. p. 518.

13. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-54.

14. Auterhoff H, Schroppel F. Borntrager-reaction with unsymmetrically substituted hydroxyanthraquinones. Arch Pharm Ber Dtsch Pharm Ges. 1969;302(12):937-40.

15. The United States Pharmacopeia. 29th ed. Rockville: United States Pharmacopeial Convention; 2006.

16. MacAnalley BH, inventor; Carrington Lab Inc., assignee. Process for preparation of aloe products. United States patent US4957907. 1989 Jan 25.

17. Martinache L, Henon MP. Concentration and desalting by ultrafiltration. In: Curling JM, editor. Methods of Plasma Protein Fractionation. London: Academic Press; 1980. p. 223-38

18. Genovesi CS. Validation of unique filtration processes. In: Carleton JF, Agalloco JP, eds. Validation of aseptic pharmaceutical processes. New York: Marcel Dekker, 1986:476-506.

19. Inzana TJ, Mathison B. Serotype specificity and immunogenicity of the capsular polymer of Haemophilus pleuropneumoniae serotype 5. Infect Immun.1987;55(7): 1580-7.

20. Kogan G, Jann B, Jann K. Structure of the Escherichia coli 0104 polysaccharide and its identity with the capsular K9 polysaccharide. FEMS Microbiol Lett. 1992; 70(2):135-40.

21. Shibata N, Ichikawa T, Tojo M, Takahashi M, Ito N, Okubo Y, et al. Immunochemical study on the mannans of Candida albicans NIH A-207, NIH B-792, and J-1012 strains prepared by fractional precipitation with cetyltrimethylammonium bromide. Arch Biochem Biophys. 1985;243(2):338-48.

22. Teixeira AZ, Iacomini M, Gorin PA. An unusual glucomannan from Tornabenia intricata. Phytochemistry. 1992;31(10):3467-70.

23. Lander RJ, Winters MA, Meacle FJ, Buckland BC, Lee AL. Fractional precipitation of plasmid DNA from lysate by CTAB. Biotechnol Bioeng. 2002;79(7):776-84.

24. Aspinall GO, editor. The Polysaccharides. Vol 1. New York: Academic Press. 1982.

25. Yu X, Sun Y, Frasch C, Concepcion N, Nahm MH. Pneumococcal capsular polysaccharide preparations may contain non-C-polysaccharide contaminants that are immunogenic. Clin Diagn Lab Immunol. 1999;6(4):519-24.

26. Tai-Nin Chow J, Williamson DA, Yates KM, Goux WJ. Chemical characterization of the immunomodulating polysaccharide of Aloe vera L. Carbohydr Res. 2005;340(6):1131-42.

27. Bushell JA, Claybourn M, Williams HE, Murphy DM. An EPR and ENDOR study of gamma- and beta-radiation sterilization in poly (lactide-co-glycolide) polymers and microspheres. J Control Release. 2005;110(1):49-57

28. Joseph A, Rencher W, inventors; Schering-Plough Healthcare Products, Inc., assignee. Nasal spray compositions. United States patent US5854269. 1998 Dec 29.